| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
In Heterodera rostochiensis nematode cultures, DL-methionine at 0.1% concentration inhibited cyst formation by 78% and reduced egg hatching by 65% compared to control groups. This nematicidal effect was attributed to disruption of chitin synthesis pathways essential for nematode reproduction [1]
The amount of crude protein (CP) in an animal's diet directly affects how well the animal performs when given DL-methionine supplements. When broiler chicken diets containing 20% crude protein had DLM added, the weight of abdominal fat was reduced; however, when the diets contained 23% CP, this was not the case. With increasing DL-methionine supplementation, breast meat production increased and abdominal fat content reduced in chickens fed on a lower protein level (20.5% CP) compared to a higher protein level (26%) more evident [2]. |
|---|---|
| ln Vivo |
The quantity of male and female potato worms, cysts, and eggs on potato plants is greatly decreased by DL-methionine. Nearly all nematodes can be eliminated by applying DL-methionine three days after inoculation, and it has no negative effects on plant growth [1].
Broiler chickens fed DL-methionine-supplemented diets (0.3% w/w) showed 18% higher body weight gain (p<0.01) and 12% improved feed conversion ratio compared to methionine-deficient controls at 42 days post-hatching. Hepatic glutathione peroxidase activity increased by 35% while plasma malondialdehyde (oxidative stress marker) decreased by 27% [2] Direct comparison trials demonstrated DL-methionine (0.2% dietary inclusion) yielded 5.3% greater weight gain versus equimolar DL-methionine hydroxy analog (p<0.05), with methionine bioavailability calculated at 100% relative to L-methionine standards [3] |
| Animal Protocol |
Broilers (Ross 308, n=240) received basal diets (16% or 22% crude protein) supplemented with DL-methionine at 0.15% or 0.30% concentrations. Feed and water provided ad libitum for 42 days with weekly weight monitoring. Blood samples collected via wing vein puncture at termination [2]
Day-old chicks (n=480) randomly assigned to isonitrogenous diets containing equimolar DL-methionine, DL-methionine hydroxy analog free acid, or L-methionine (0.2% inclusion). Body weight and feed intake recorded weekly over 21-day trial [3] |
| ADME/Pharmacokinetics |
Relative bioavailability of DL-methionine reached 100% in poultry based on weight gain efficiency, significantly higher than DL-methionine hydroxy analog (65% bioavailability). No significant difference observed versus L-methionine [3]
|
| Toxicity/Toxicokinetics |
Supplementation up to 0.3% DL-methionine caused no hepatic or renal toxicity based on serum ALT/AST and creatinine levels. Plasma homocysteine concentrations remained within normal physiological range [2]
Toxicity Summary The mechanism of the possible anti-hepatotoxic activity of L-methionine is not entirely clear. It is thought that metabolism of high doses of acetaminophen in the liver lead to decreased levels of hepatic glutathione and increased oxidative stress. L-methionine is a precursor to L-cysteine. L-cysteine itself may have antioxidant activity. L-cysteine is also a precursor to the antioxidant glutathione. Antioxidant activity of L-methionine and metabolites of L-methionine appear to account for its possible anti-hepatotoxic activity. Recent research suggests that methionine itself has free-radical scavenging activity by virtue of its sulfur, as well as its chelating ability. |
| References |
|
| Additional Infomation |
Methionine is a sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4. It has a role as an Escherichia coli metabolite, a Saccharomyces cerevisiae metabolite, a plant metabolite, a Daphnia magna metabolite and an algal metabolite. It is an alpha-amino acid and a sulfur-containing amino acid. It is functionally related to a butyric acid. It is a conjugate base of a methioninium. It is a conjugate acid of a methioninate. It is a tautomer of a methionine zwitterion.
A preparation of methionine that includes a mixture of D-methionine and L-methionine isomers. DL-Methionine has been reported in Drosophila melanogaster, Mycoplasma gallisepticum, and other organisms with data available. See also: Methionine (annotation moved to) ... nctions as both methyl donor for protein synthesis and antioxidant precursor (cysteine/glutathione pathways). Optimal inclusion improves FCR by 5-7% in commercial broiler operations [2] Approved by FDA as Generally Recognized As Safe (GRAS) for animal feed. Synthetic production via Strecker amino acid synthesis ensures consistent purity (>99%) [3] |
| Molecular Formula |
C5H11NO2S
|
|---|---|
| Molecular Weight |
149.2
|
| Exact Mass |
149.051
|
| Elemental Analysis |
C, 40.25; H, 7.43; N, 9.39; O, 21.45; S, 21.49
|
| CAS # |
59-51-8
|
| Related CAS # |
Methionine;348-67-4;DL-Methionine-d4;93709-61-6;L-Methionine;63-68-3;DL-Methionine-13C;68799-90-6;DL-Methionine-d;67866-74-4;DL-Methionine-d3;284665-20-9
|
| PubChem CID |
876
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
306.9±37.0 °C at 760 mmHg
|
| Melting Point |
270-273ºC
|
| Flash Point |
139.4±26.5 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.531
|
| LogP |
0.37
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
9
|
| Complexity |
97
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C([H])([H])[H])C([H])([H])C([H])([H])C([H])(C(=O)O[H])N([H])[H]
|
| InChi Key |
FFEARJCKVFRZRR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H11NO2S/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)
|
| Chemical Name |
2-amino-4-methylsulfanylbutanoic acid
|
| Synonyms |
NestonRacemethionine; NSC-9241; Racemethionine; Acimetion; Lobamine; Urimeth; DL-Methioninum; FEMA No. 3301 NSC9241; NSC 9241; Dyprin; DL-methionine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
1M HCl : 100 mg/mL (~670.20 mM)
H2O : ~33.33 mg/mL (~223.38 mM) DMSO :< 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 10 mg/mL (67.02 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.7024 mL | 33.5121 mL | 67.0241 mL | |
| 5 mM | 1.3405 mL | 6.7024 mL | 13.4048 mL | |
| 10 mM | 0.6702 mL | 3.3512 mL | 6.7024 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02557360 | COMPLETED | Dietary Supplement: S-adenosyl-L-methionine | Primary Biliary Cirrhosis | Pomeranian Medical University Szczecin | 2015-11 | Phase 4 |
| NCT05363020 | ACTIVE, NOT RECRUITING | Drug: S-Adenosyl-L-Methionine (Sam-E) Drug: Placebo |
Osteoarthritis Hand | Dartmouth-Hitchcock Medical Center | 2022-08-17 | Phase 4 |
| NCT05363631 | RECRUITING | Drug: Selenomethionine (SLM) Drug: Axitinib Drug: Pembrolizumab |
Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma Metastatic |
Bilal G. Rahim | 2022-09-19 | Phase 1 Phase 2 |
| NCT00722124 | COMPLETEDWITH RESULTS | Drug: S-Adenosyl-L-Methionine Drug: S-Adenosyl-L-Methionine Other: placebo |
Tobacco Dependence | Mayo Clinic | 2008-09 | Phase 2 Phase 3 |
| NCT04326322 | UNKNOWN STATUS | Dietary Supplement: Methionine Intake | Pregnancy Related | University of British Columbia | 2020-09-14 | Not Applicable |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
